首页 > 市场调查报告书 > 医疗设备

生技设备

市场调查报告书

商品编码

1634195

全球微流体市场 - 2025 - 2033

Global Microfluidics Market - 2025 - 2033

出版日期: 2025年01月13日 | 出版商:

DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024年全球微流控市场规模达283.8亿美元，预估至2032年将达739.7亿美元，2025-2032年预测期间复合年增长率为12.6%。

微流体学研究流体流经微通道的行为，以及涉及製造包含流体流动或限制的腔室和通道的微型装置的技术。该领域的特点是专注于非常少量的流体，通常范围从微升（10^-6 升）到飞升（10^-15 升）。

微流控由微流控元件和微流控装置组成。微流体组件是微流体系统的组成部分，旨在微尺度上操纵和分析少量流体。微流体设备是先进的系统，旨在使用微通道和腔室网路操纵、控制和分析少量流体。

产业研究活动的主要参与者和创新平台的引入推动了微流体市场的成长。例如，2023 年 2 月，印度推出了第一个专为 mRNA 疫苗临床前快速开发而设计的微流体平台，在疫苗开发方面取得了重大进展。这个创新平台旨在简化 mRNA 疫苗的创建和测试过程，这种疫苗以其快速的开发时间表和针对传染病的有效性而闻名。这些因素推动了全球微流体市场的扩张。

市场动态：

驱动程式和限制

对即时检测 (POCT) 的需求不断增加

对即时检测 (POCT) 的需求不断增长，极大地推动了全球微流体市场的成长，预计将在整个市场预测期内持续成长。

护理点检测 (POCT) 在临床环境中变得越来越重要，因为它能够直接在患者护理现场提供快速诊断结果。这种能力在紧急情况和农村医疗保健环境中尤其重要，因为传统实验室的访问可能受到限制。微流控设备是这一趋势的核心，能够以最小的样本量进行快速、准确的测试，这对于及时诊断和治疗至关重要。

随着医疗保健系统努力提高效率并降低成本，对即时检测 (POCT) 的需求激增。这一趋势很大程度上归因于微流体能够提供可在传统实验室环境之外进行的快速诊断，从而改变患者护理和操作效率。

此外，产业研究活动以及伙伴关係和协作的主要参与者将推动微流体市场的成长。根据PIB 2024 年8 月新闻报道，研究人员开发了一种液滴微流体技术，能够生产具有高电活性(EA) 相的微球，这对于创建适用于可穿戴应用的高效且经济高效的压电设备至关重要。这项进步意义重大，因为它为监测各种生理讯号的自供电感测器铺平了道路。

同样，2023 年 4 月，Molbio Diagnostics 和 SigTuple 正在合作开发下一代护理点 (POC) 诊断设备，该设备利用人工智慧 (AI) 和机器学习 (ML) 等先进技术。

SigTuple 为此次合作带来了人工智慧和微流体技术的专业知识。透过将人工智慧和机器学习融入 POC 设备中，此次合作旨在提高诊断准确性和速度。该公司成立的愿景是利用人工智慧、机器人技术和微流体技术创建可部署在服务不足地区的智慧诊断解决方案。这种方法解决了医疗保健取得方面的关键差距，特别是在传统实验室设施稀缺的地区。所有这些因素都需要全球微流体市场。

此外，慢性病发病率的上升和技术进步预计将在预测期内推动微流体市场的发展。

研发成本高

高昂的研发成本将阻碍全球微流体市场的成长。建立微流体製造和研发设施所需的大量初始投资给公司带来了巨大的障碍，特别是在发展中地区。微流体需要先进的机械和技术来在微观尺度上操纵流体，其中包括昂贵的製造工具、无尘室环境和高解析度成像系统。

例如，微流体实验室的设置成本通常约为 30,000 美元至 65,000 美元，具体取决于所使用的设备和材料。此成本包含有效微流体研究和开发所需的几个基本组成部分。

洁净室条件以防止生产过程中的污染的必要性进一步增加了设置成本，使得财力有限的小公司难以进入市场。此外，微流体技术的复杂性需要跨学科的高技能劳动力，包括工程、物理、化学和生物学。招募和培训此类专业人士既耗时又昂贵，导致资本支出高昂。所有这些因素预计都会阻碍微流体市场。因此，上述因素可能限制全球微流体市场的潜在成长。

Microfluidics studies the behavior of fluids flowing through micro-channels and the technology that involves manufacturing microminiaturized devices containing chambers and channels through which fluids flow or are confined. This field is characterized by its focus on very small volumes of fluids, typically ranging from microliters (10^-6 liters) to femtoliters (10^-15 liters).

Microfluidics consists of microfluidic components and microfluidic devices. Microfluidic components are integral parts of microfluidic systems designed to manipulate and analyze small volumes of fluids at a microscale. Microfluidics devices are advanced systems designed to manipulate, control, and analyze small volumes of fluids using networks of microchannels and chambers.

Key players in the industry research activities and the introduction of innovative platforms drive the microfluidics market growth. For instance, in February 2023, India made a significant advancement in vaccine development by introducing its first microfluidic platform designed specifically for the rapid preclinical development of mRNA vaccines. This innovative platform aims to streamline the process of creating and testing mRNA vaccines, which are known for their quick development timelines and effectiveness against infectious diseases. These factors have driven the global microfluidics market expansion.

Market Dynamics: Drivers & Restraints

Increasing Demand for Point-of-Care Testing (POCT)

The increasing demand for point-of-care testing (POCT) is significantly driving the growth of the global microfluidics market and is expected to drive throughout the market forecast period.

Point-of-care testing (POCT) is increasingly vital in clinical settings due to its ability to deliver rapid diagnostic results directly at the site of patient care. This capability is particularly crucial in emergency and rural healthcare environments, where traditional laboratory access may be limited. Microfluidic devices are central to this trend, enabling quick, accurate testing with minimal sample volumes, which is essential for timely diagnosis and treatment.

As healthcare systems strive to enhance efficiency and reduce costs, the demand for point-of-care testing (POCT) has surged. This trend is largely due to the ability of microfluidics to provide rapid diagnostics that can be performed outside traditional laboratory settings, thereby transforming patient care and operational efficiency.

Furthermore, key players in the industry research activities, and partnerships & collaborations, would drive this microfluidics market growth. As per PIB news in August 2024, researchers have developed a droplet microfluidics technology that enables the production of microspheres with a high electroactive (EA) phase, which is crucial for creating efficient and cost-effective piezoelectric devices suitable for wearable applications. This advancement is significant as it paves the way for self-powered sensors that monitor various physiological signals.

Similarly, in April 2023, Molbio Diagnostics and SigTuple are collaborating to develop next-generation point-of-care (POC) diagnostic devices that leverage advanced technologies such as artificial intelligence (AI) and machine learning (ML).

SigTuple brings expertise in AI and microfluidics technologies to the partnership. By incorporating AI and ML into the POC devices, the collaboration seeks to improve diagnostic accuracy and speed. The company was founded with the vision of using AI, robotics, and microfluidics to create intelligent diagnostic solutions that can be deployed in underserved areas. This approach addresses critical gaps in healthcare access, particularly in regions where traditional laboratory facilities are scarce. All these factors demand the global microfluidics market.

Moreover, the rising incidence of chronic diseases and technological advancements are the factors expected to drive the microfluidics market over the forecast period.

High Research and Development Costs

The high research and development costs will hinder the growth of the global microfluidics market. The substantial initial investment needed to set up microfluidic manufacturing and R&D facilities creates a significant barrier for companies, especially in developing regions. Microfluidics requires advanced machinery and technology to manipulate fluids at a microscopic scale, which includes costly fabrication tools, cleanroom environments, and high-resolution imaging systems.

For instance, the setup cost for a microfluidic lab typically ranges from approximately $30,000 to $65,000, depending on the equipment and materials used. This cost encompasses several essential components necessary for effective microfluidic research and development.

The necessity for cleanroom conditions to prevent contamination during production further escalates setup costs, making it difficult for smaller firms with limited financial resources to enter the market. Additionally, the complexity of microfluidic technologies demands a highly skilled workforce across various disciplines, including engineering, physics, chemistry, and biology. Recruiting and training such expertise is both time-consuming and expensive, contributing to high capital expenditures. All these factors are expected to hamper the microfluidics market. Thus, the above factors could be limiting the global microfluidics market's potential growth.

Segment Analysis

The global microfluidics market is segmented based on product type, material, application, end-user, and region.

Product Type:

The microfluidic components segment is expected to dominate the global microfluidics market share

The microfluidic components segment holds a major portion of the global microfluidics market share and is expected to continue to hold a significant portion of the global microfluidics market share during the forecast period.

Microfluidic components are essential elements in the design and functionality of microfluidic systems, which are increasingly utilized across various fields such as biomedical research, diagnostics, and chemical synthesis. These components enable the manipulation, mixing, and analysis of fluids at a microscale, providing significant advantages over traditional methods.

The microfluidic component consists of microfluidic chips, micro pumps, and others. Microfluidic chips are the foundational elements of microfluidic systems. They consist of a network of microchannels and chambers that facilitate fluid manipulation.

Micropumps are essential devices within microfluidic systems that control the movement of fluids through the microchannels. These pumps enable accurate dosing and transport of liquids, which is crucial for maintaining precise flow rates during experiments. They can be pressure-driven or utilize other mechanisms such as electrokinetic forces to move fluids.

Furthermore, key players in the industry product launches and manufacturing facilities that would propel this segment's growth in the microfluidics market. For instance, in September 2022, Dolomite Bio is launching a compact, affordable microfluidic system for custom microfluidic and genomics research. This new system combines the microfluidic technology underlying their Nadia Instrument, with the customizable parameters of the Nadia Innovate. It grants access to the custom microfluidic protocol development without the necessity of a large capital outlay.

Similarly, in January 2024, uFluidix made significant strides in the manufacturing of thermoplastic microfluidic chips over the past year. The company has successfully doubled its manufacturing capacity and is now focusing on optimizing new process variables to enhance production efficiency and product quality. This initiative is particularly relevant as the demand for microfluidic devices continues to grow across various applications, including biomedical and diagnostic fields. These factors have solidified the segment's position in the global microfluidics market.

Geographical Analysis

North America is expected to hold a significant position in the global microfluidics market share

North America holds a substantial position in the global microfluidics market and is expected to hold most of the market share.

The growing prevalence of chronic diseases such as diabetes, cancer, and cardiovascular conditions significantly drives the demand for innovative diagnostic tools. Microfluidics technology plays a crucial role in addressing this need by enabling efficient monitoring and management of these diseases through rapid testing and personalized medicine approaches.

North America is recognized for its well-developed healthcare system, which significantly supports the integration and adoption of advanced technologies such as microfluidics. This robust infrastructure facilitates the implementation of microfluidic devices across various applications, particularly in diagnostics and drug delivery.

Moreover, in this region, a major number of key players' presence, government initiatives & regulatory support, and technological advancements, & investments would propel this microfluidics market growth. For instance, in May 2024, Takara Bio USA, Inc. introduced the Lenti-X Transduction Sponge, an innovative product designed to enhance lentivirus-mediated gene delivery. This innovative tool is notable for being the first dissolvable microfluidic transduction enhancer on the market, streamlining in vitro gene delivery processes. Thus, the above factors are consolidating the region's position as a dominant force in the global microfluidics market.

Asia Pacific is growing at the fastest pace in the global microfluidics market share

Asia Pacific holds the fastest pace in the global microfluidics market and is expected to hold most of the market share.

The prevalence of chronic diseases, including diabetes, cancer, and cardiovascular conditions, is on the rise in the Asia-Pacific region. This trend necessitates the development of efficient diagnostic instruments and treatment options, further propelling the demand for microfluidic technologies. The need for rapid, cost-effective diagnostic tools and precision healthcare solutions is a major driver of the microfluidics market. Devices such as lab-on-a-chip and point-of-care testing systems are essential for delivering quick diagnostics, which are particularly valuable in managing chronic diseases and infectious conditions.

Innovations in microfluidic technology are expanding their applications across various sectors, including healthcare, environmental monitoring, and food safety. These advancements enable more efficient biochemical analyses using smaller sample sizes, making them ideal for clinical diagnostics and pharmaceutical research. Rapid advancements in healthcare infrastructure across countries like China, India, and Japan are facilitating the adoption of advanced medical technologies. Increased investment in biotechnology and medical research is establishing the Asia-Pacific region as a hub for microfluidics development.

Microfluidics plays a significant role in personalized medicine by enabling tailored treatment strategies based on individual patient profiles. This focus on personalized healthcare solutions is boosting the demand for microfluidic devices that can support such applications. Many governments in the Asia-Pacific region are implementing policies that promote research and development in microfluidics. This support fosters innovation and accelerates market growth by providing financial assistance and creating favorable regulatory environments.

Furthermore, key players in the industry product launches that would drive this microfluidics market growth in the region. For instance, in February 2023, Mumbai-based Amar Equipment launched NanoMake, which is recognized as India's first microfluidic platform aimed at accelerating preclinical development for mRNA vaccines and nano-formulations. This significant announcement was made during the Biosimilar Workshop held at the Institute of Chemical Technology, one of the largest gatherings of biopharmaceutical researchers in India. Thus, the above factors are consolidating the region's position as the fastest-growing force in the global microfluidics market.

Competitive Landscape

The major global players in the microfluidics market include Thermo Fisher Scientific Inc., PerkinElmer, Agilent Technologies, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., Standard BioTools (Fluidigm Corporation), Merck KGaA, Sphere Fluidics., uFluidix, and Emulate Inc. among others.

Key Developments

In November 2024, LumiraDx introduced a Rapid Microfluidic Immunoassay C-Reactive Protein (CRP) Test aimed at addressing antimicrobial resistance (AMR) in India. This innovative test is designed to provide quick and accurate results, enabling healthcare providers to make informed decisions regarding the use of antibiotics.

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
Post-market Surveillance: Uses post-market data to enhance product safety and access.
Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global microfluidics market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Material
3.3. Snippet by Application
3.4. Snippet by End-User
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing Demand for Point-of-Care Testing (POCT)
- 4.1.2. Restraints
  - 4.1.2.1. High Research and Development Costs
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
5.5. Regulatory Analysis
5.6. SWOT Analysis
5.7. Unmet Needs

6. By Product Type

6.1. Introduction
- 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 6.1.2. Market Attractiveness Index, By Product Type
6.2. Microfluidic-Based Devices*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Microfluidic Components
- 6.3.1. Microfluidic Chips
- 6.3.2. Micro Pumps
- 6.3.3. Microneedles
- 6.3.4. Others
6.4. Others

7. By Material

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 7.1.2. Market Attractiveness Index, By Material
7.2. Polymer*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Silicon
7.4. Glass
7.5. Others

8. By Application

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
8.2. Drug Delivery*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Point-of-Care Diagnostics
8.4. Pharmaceutical and Biotechnology Research:
- 8.4.1. High-throughput Screening
- 8.4.2. Proteomics
- 8.4.3. Genomics
- 8.4.4. Cell-based Assays
- 8.4.5. Capillary Electrophoresis
- 8.4.6. Others
8.5. Clinical Diagnostics
8.6. Others

9. By End-User

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.1.2. Market Attractiveness Index, By End-User
9.2. Hospitals and Diagnostic Centers*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Academic and Research Institutes
9.4. Pharmaceutical and Biotechnology Companies

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.7.1. U.S.
  - 10.2.7.2. Canada
  - 10.2.7.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.7.1. Germany
  - 10.3.7.2. U.K.
  - 10.3.7.3. France
  - 10.3.7.4. Spain
  - 10.3.7.5. Italy
  - 10.3.7.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.7.1. Brazil
  - 10.4.7.2. Argentina
  - 10.4.7.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.7.1. China
  - 10.5.7.2. India
  - 10.5.7.3. Japan
  - 10.5.7.4. South Korea
  - 10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. Thermo Fisher Scientific Inc.*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. PerkinElmer
12.3. Agilent Technologies, Inc.
12.4. Illumina, Inc.
12.5. Bio-Rad Laboratories, Inc.
12.6. Standard BioTools (Fluidigm Corporation)
12.7. Merck KGaA
12.8. Sphere Fluidics.
12.9. uFluidix
12.10. Emulate Inc.

LIST NOT EXHAUSTIVE